Introduction
Vectors based on adeno-associated virus (AAV), a nonpathogenic, replication-defective human parvovirus, have several attributes that make them highly suitable for gene transfer into post-mitotic tissues. Foremost among these is the fact that a single administration of recombinant AAV (rAAV) into the muscle, liver, retina or the brain results in long-term transgene expression without toxicity in a variety of animal models. 1 These preclinical studies have lead to a series of phase-I/II gene therapy trials with AAV serotype 2, the first isolate to be fully characterized. A diverse range of disorders have been targeted including hemophilia B, a-1-antitrypsin deficiency, Duchene muscular dystrophy, Leber's congenital amaurosis, leukodystrophies and Parkinson's disease. [2] [3] [4] [5] [6] These early human studies have identified several obstacles that need to be addressed before the potential of AAV vectors can be fully realized. First, pre-existing immunity to viral capsid is a significant impediment to stable transgene expression. 3 As wildtype (wt) AAV2 is endemic to humans, the majority of individuals participating in these clinical trials likely had pre-existing immunity to this serotype as a result of prior natural infection. Anti-AAV2 antibodies have the potential to block or greatly reduce gene transfer with rAAV2 vectors. In addition, the cytotoxic T cells generated at the time of infection with wt-AAV can expand and eliminate cells that are transduced, as suggested by the results of a recent hemophilia B gene therapy trial. 3 A strategy to overcome these immunological obstacles involves the switching of capsid protein to those serotypes of AAV that are less prevalent in the humans. [7] [8] [9] A large number of AAV serotypes have recently been described and need to be systematically evaluated in preclinical models to facilitate their transition to the clinic. 10, 11 Another limitation to the clinical use of AAV vectors is the need for high multiplicity of infection to achieve therapeutic gene transfer. For instance, an excess of 10 14 AAV2 vector particles were required for therapeutic transgene expression from the liver in subjects with severe hemophilia B. 3 Efficient transduction of target cells is blocked at several levels including ineffective endocytosis, endosomal degradation, inefficient uncoating and the need to convert the single-stranded AAV genome to a transcriptionally active double-stranded form. [12] [13] [14] The latter process may be influenced by host factors such as gender. 15 A better understanding of these biological limitations has resulted in novel strategies to improve transduction with single-stranded AAV. For instance, blockade of endosomal degradation of AAV with proteasome inhibitors significantly augments transduction in mice. 16 The clinical exploitation of this strategy will be further facilitated by demonstrating the same effect with clinically relevant proteasome inhibitors. The efficiency with which the vectors uncoat and release their genome can be enhanced by switching AAV capsid protein to that of an alternative serotype such as AAV8. 7, 17 This is partly responsible for improving the transduction of murine hepatocytes with AAV8 when compared with vectors pseudotyped with serotype 2 capsid.
Possibly, the most important impediment to efficient gene transfer with AAV vectors is the need to convert the single-stranded AAV genome to a transcriptionally active double-stranded form. [12] [13] [14] This complex process is inefficient and appears to be influenced by additional host factors such as gender. 15 Consequently, the majority of the single-stranded AAV genome that enters the nucleus is degraded. A solution to this problem has been derived by modifying the AAV genome such that complementary proviral single-stranded molecules are packaged within a single virion. 8, 18, 19 After uncoating, these complementary strands anneal to form stable transcriptionally active dimers. These self-complementary AAV vectors (scAAVs) mediate stable transduction of the liver, which is almost a log higher than that achieved with an equivalent dose of comparable singlestranded rAAV. 8, 18, 19 This raises the possibility of mediating therapeutic gene transfer with significantly lower doses of scAAV vector, which has favorable safety implications and may ease the burden on vector production. Hence, there is significant interest in this new generation of AAV vectors, but it is unclear whether the upstream obstacles that restricted gene transfer with single-stranded AAV vectors, such as proteasome degradation, will also impair the efficiency of scAAV vectors.
Another unanswered question relates to the consequences of delayed exposure to helper virus during the viremic phase of a natural infection with adeno or herpes virus, as may occur in patients whose hepatocytes have been stably transduced with rAAV vector. These helper viruses play an important role in virtually all aspects of the life cycle of wt-AAV. For instance, the adenoviral E1, E2a and E4 (orf6) genes and the VA1 RNA interact with the AAV inverted terminal repeats (ITRs) and the rep and cap genes to facilitate rescue and replication of the wt provirus. Coadministration of rAAV vectors, which lack the wt rep and cap genes, with adenovirus significantly enhances AAV transduction because of the efficient synthesis of double-stranded transcriptionally active viral genome. 20 As infection with these helper viruses is common in humans, their effects on expression mediated by stably retained transgene following rAAV gene transfer need to be defined. 21 In this study, transduction of the murine liver with scAAV vector pseudotyped with capsid proteins derived from four different recently isolated non-human serotypes of AAV was compared. The minimum vector dose required for therapeutic transgene expression in mice was defined. In addition, we determined whether scAAV-mediated gene transfer into murine hepatocytes is influenced by gender and administration of a clinically available proteasome inhibitor. The consequences of late infection with adenovirus on AAV-mediated gene transfer in murine liver were also investigated.
Results

Transduction of murine liver with alternative AAV serotypes
These experiments were performed with our previously described scAAV vector cassette encoding human FIX under the control of a liver-specific promoter (LP1-hFIXco) flanked by AAV2 ITRs. 8 The use of scAAV dispenses with the need for second-strand synthesis, thus removing a confounding variable. scAAV-LP1-hFIXco vectors pseudotyped with AAV-7, -8, -9 and rh.10 capsid were generated using previously described chimeric packaging plasmids encoding AAV2-rep, positioned upstream of the cap genes from serotype 7, 8, 9 or rh.10. 10, 11, 22 All pseudotyped scAAV vectors were purified using iodixanol density centrifugation. SDS-polyacrylamide gel electrophoresis of the resulting vector stock demonstrated a similar high level of purity (o20% contaminating proteins). Equivalent numbers of vector genomes (range: 4 Â 10 8 -2 Â 10 11 vector genome per kg (vg kg À1 )), as determined by quantitative real-time PCR (qPCR), were then injected into the tail vein of 6-to 8-week-old male C57Bl/6 mice (n ¼ 5-8 animals per cohort) to determine the efficiency with which these pseudotyped AAV vectors transduced the liver. The LP1 promoter has previously been shown to restrict transcription to hepatocytes; therefore, circulating hFIX protein detected following administration of scAAV-LP1-hFIXco was assumed to result from its expression in the liver. 8 At all doses assessed and for each pseudotyped vector, the profile of transgene expression generated from alternative scAAV vectors was similar (Figure 1 ). Plasma hFIX levels were detectable within 24 h and increased rapidly to peak values by 7 days after vector administration. Thereafter, the expression stabilized for the duration of the study (57 days). scAAV pseudotyped with serotype 8 and rh.10 capsid proteins gave the highest levels of expression at all doses and time points. Fifty-seven days after tail vein administration of 2 Â 10 11 vg kg
À1
, the mean hFIX levels were 36±0.3 and 34.0 ± 0.2 mg ml À1 in the scAAV-2/8 and -2/rh.10 cohort of mice, respectively. These levels correspond to almost 700% of normal hFIX levels in humans. When the vector dose was reduced to 4 Â 10 10 vg kg
, the expression of hFIX in the scAAV-2/8 and -2/rh.10 cohorts was still almost 250% of physiological values at 13±4 and 12 ± 2 mg ml À1 , respectively. Although the mean hFIX level in animals transduced with 4 Â 10 10 vg kg À1 of scAAV2/9-LP1-hFIXco was lower at 7 ± 3 mg ml À1 , this difference was not statistically significant when compared with the expression in the serotype 8 and rh.10 cohorts. In contrast, mice transduced with 4 Â 10 10 vg kg
of scAAV-LP1-hFIXco pseudotyped with capsid from AAV7 had an almost fourfold lower level of hFIX expression (3 ± 1 mg ml À1 ) when compared with the scAAV-2/8 and -2/rh10 cohorts (P ¼ 0.0002, one-way analysis of variance). For each serotype, there was a roughly linear relationship between the number of vector particles administered and the hFIX levels in murine plasma. Despite its comparatively lower hepatocyte gene transfer efficiency, the mean plasma hFIX level (0.06 ± 0.01 mg ml
) observed after tail vein administration of the lowest dose of scAAV2/7-LP1-hFIXco (4 Â 10 8 vg kg
) was significantly above the Liver transduction with adeno-associated viral vectors AC Nathwani et al threshold (0.05 mg ml À1 , 1% of normal) required to ameliorate the bleeding phenotype in patients with severe hemophilia B.
Biodistribution of AAV vectors of alternate serotypes
We next evaluated the differences in biodistribution of the vector genome following tail vein administration of 4 Â 10 9 vg kg À1 of each pseudotyped scAAV vector in mice. The proviral copy number as assessed by qPCR analysis of genomic DNA extracted from the liver, spleen, heart, kidneys, lungs and testes of mice (N ¼ 3) killed 8 weeks after vector administration was consistent for each set of tissues within serotype grouping but varied substantially between different tissue sites and serotypes. The liver was the most efficiently transduced, with at least 40-fold more vector genome copies per cell (vg per cell) when compared with non-hepatic tissues (Table 1 and Figure 2 ). This is consistent with the earlier reports of preferential transduction of the liver following tail vein administration of AAV vectors. The average transgene copy number in the liver of mice transduced with vector pseudotyped with serotype 8 and rh.10 capsid was 3 ± 1 and 3 ± 0.5 transgene copies per cell, respectively. This is significantly higher (Po0.001, twoway analysis of variance) than the levels observed in the liver of animals transduced with scAAV-2/7 (0.7±0.2 vg per cell) and -2/9 (1 ± 0.2 vg per cell). Notably, the ratio of plasma hFIX level to transgene copy number in the liver was similar for scAAV vectors pseudotyped with serotype 7, 8 and rh.10 capsid protein but was twofold higher for scAAV2/9. This suggests that AAV9 capsid may influence efficiency of transgene expression ( Table 1) .
Biodistribution of the vector to the non-hepatic tissues was also influenced by the AAV capsid proteins ( Figure 2 ). scAAV2/rh.10 appeared to be most efficient at transducing the spleen (0.08 ± 0.03 vg per cell), with moderate levels of gene transfer into the heart and lungs (0.04 ± 0.01 vg per cell) and a relatively low copy number in the kidneys (0.02±0.002 vg per cell). In comparison, scAAV-2/9 and -2/8 vectors were less efficient at transducing the lungs, but moderate level of gene transfer was observed into the heart and spleen (average of 0.03 ± 0.001 vg per cell). The lungs (0.02 ± 0.005 vg per cell) were most efficiently transduced with AAV serotype 7 pseudotyped vectors. The kinetics of the humoral response to viral capsid proteins was identical for the four different pseudotypes of scAAV assessed. Anti-AAV capsid IgG was detectable within 7-10 days of tail vein administration of vector. The antibody titers reached peak levels within 3 weeks, which were then stably maintained for the duration of the study. The neutralizing potential of these antibodies was confirmed using a transduction inhibition assay (data not shown). Eight weeks after gene transfer with 4 Â 10 10 vg kg À1 of scAAV-2/8 or -2/rh.10, mice from each of these two cohorts were challenged with a second tail vein administration of AAV (4 Â 10 10 vg kg
À1
), this time encoding human coagulation factor VII (rAAVhFVII) under the control of the LP1 promoter pseudotyped with either serotype 8 or rh.10 capsid protein. Secondary challenge with vectors based on the same serotype did not result in any gene transfer as assessed by the plasma expression of hFVII ( Figure 3 ). Mice previously exposed to scAAV2/rh.10-LP1-hFIXco were successfully transduced with rAAV-hFVII pseudotyped with serotype 8 capsid, resulting in mean steady-state plasma hFVII levels of 4 ± 0.4% of normal, which is comparable to the transgene expression achieved in naive control animals (5 ± 0.4% of normal) not previously sensitized to AAV. Similar results were obtained when mice previously exposed to scAAV2/8-LP1-hFIXco were challenged with rAAV-hFVII pseudotyped with rh.10 capsid protein. Thus, despite the close (93%) amino-acid sequence homology between AAV8 and rh.10 capsid, vectors pseudotyped with alternative serotype can overcome serotype-specific antibodies.
Bortezomib influences AAV-mediated gene transfer especially in female mice
We have shown earlier that gender significantly influences liver transduction with single-stranded AAV through the binding of a nuclear protein to the Repbinding site on AAV-2 ITR. 15 It was hypothesized that this interaction facilitated de novo second-strand synthesis. As scAAV vectors dispense with the need for second-strand synthesis, we assessed the influence of gender on hepatocyte gene transfer with this vector configuration. As shown in Figure 4 , tail vein administration of 4 Â 10 10 vg kg À1 scAAV2/8-LP1-hFIXco into 8-to 10-week-old C57Bl/6 mice resulted in systemic expression of hFIX in male mice, which was almost twofold higher (7±1 mg ml À1 , N ¼ 7) when compared with the levels achieved in the female cohort (4±0.6 mg ml
À1
, N ¼ 8). This is significantly less than the previously reported 10-fold difference in transgene expression between male and female mice following tail vein administration of single-stranded rAAV vectors. 15 We next investigated if bortezomib, a clinically available proteasome inhibitor, could augment scAAV-mediated transduction of the murine liver. Tail vein injection of bortezomib (1 mg mg À1 ), 24 h before administration of scAAV2/8-LP1-hFIXco, increased hFIX expression in female mice by twofold to 9 ± 2 mg ml À1 (N ¼ 8, P ¼ 0.02). Male mice treated with bortezomib had a more modest but significant (P ¼ 0.04) increase in transgene expression, with steady-state hFIX levels of 10 ± 1 mg ml À1 (N ¼ 7). Notably, the level of hFIX observed in male and female mice conditioned with bortezomib was comparable. Readministration of bortezomib at 24 h after transduction with scAAV2/8-LP1-hFIXco did not result in a significant further increase in hFIX expression in male (11 ± 2 mg ml À1 ) or female mice (11 ± 1 mg ml À1 ) conditioned with this agent before vector administration. In contrast, a single administration of bortezomib after vector administration (at 24 h) did not abrogate the gender difference (data not shown). Table 1 ) and non-hepatic tissues (presented in the graph). Transgene copy number in each tissue was quantified by a vector-specific qPCR assay. Shown is transgene copy number per diploid genome corrected for variation in loading and amplification efficiency using GAPDH primers. qPCR, quantitative real-time PCR; scAAV, self-complementary AAV vector.
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Delayed administration of E1/E3-deleted adenoviral vectors enhances stable rAAV-mediated transgene expression
Previously, it had been demonstrated that coadministration of single-stranded rAAV vectors with adenovirus significantly enhanced the conversion to a doublestranded, more stable form, thereby increasing transgene expression.
14 To determine the consequences of delayed administration of adenovirus, at a time when all the genome of a single-stranded rAAV has been converted to a double-stranded form, we used our previously described single-stranded vector consisting of CMV-IE enhancer, b-actin promoter (CAGG) directing the Liver transduction with adeno-associated viral vectors AC Nathwani et al expression of hFIX cDNA. 23 A dose of 2 Â 10 12 vg kg À1 of rAAV2-CAGG-FIX was injected into the portal vein of two groups of 8-to 10-week-old male mice. The kinetics of expression in these animals was consistent with that reported previously, with stable levels of hFIX (0.12±0.02 mg ml ), an E1/E3-deleted adenovirus serotype 5 vector particle encoding the b-galactosidase gene under the control of the CMV promoter, was administered in a proportion of mice at 10 weeks after administration of rAAV2-CAGG-FIX. This resulted in a rapid increase in hFIX levels that peaked at 0.28±0.02 mg ml À1 before declining to steady-state levels of 0.2 ± 0.01 mg ml
À1
, which were still significantly higher than the pretreatment values (P ¼ 0.004 by Student's t-test). We speculate that the decline, which follows the increase, in rAAV transgene expression after late administration of adenovirus is because of immune-based elimination of a proportion of hepatocytes stably transduced with AAV that have subsequently been infected with adenovirus. Southern blot analysis of genomic DNA extracted from the liver at 24 weeks after gene transfer with rAAV2-CAGG-FIX (14 weeks after administration of AV5LacZ) demonstrated that the hFIX transgene copy number was not significantly altered by administration of AV5LacZ and ranged between 0.1 and 0.25 copies per cell, which was comparable to that seen in ) + + --N Figure 5 (a) Human FIX expression (mean±s.e.m.) following tail vein administration of 2 Â 10 12 vg kg À1 rAAV2 CAGG-FIX vector particles in C57Bl/6 mice (n ¼ 6 per cohort). AV5LacZ (4 Â 10 9 vg kg À1 ), an E1/E3-deleted adenoviral vector encoding the b-galactosidase gene, was administered into one cohort (n) at 10 weeks after rAAV2 CAGG-FIX-mediated gene transfer. The second cohort received an equal volume of PBS (B). (b) Genomic DNA (top panel) and total cellular RNA (bottom panel) were extracted from the liver of mice that had been sequentially transduced with rAAV2 CAGG-FIX and AV5LacZ adenoviral particles (as described above). rAAV transgene copy number was determined by digesting 10 mg of DNA with NheI followed by Southern blot transfer and hybridization with an hFIX-specific probe. Northern blot transfer of 10 mg of total hepatocellular RNA onto nylon membrane followed by hybridization with an hFIX-specific probe. N ¼ samples from naive mouse, À indicates samples from mice exposed to rAAV2 CAGG-FIX only and + indicates mice sequentially transduced with rAAV2 and adenovirus. Liver transduction with adeno-associated viral vectors AC Nathwani et al control animals. This contrasts with the increase in transgene copy number that occurs when adenovirus is administered concurrently with single-stranded AAV. 14 Northern blot analysis revealed 10-fold higher hFIX mRNA levels in the liver of rAAV2-CAGG-FIX-transduced animals that were exposed to adenovirus when compared with controls, consistent with an increase in the transcription or stability of the rAAV2-CAGG-FIX mRNA.
We next determined if the increase in AAV proviral mRNA by adenovirus was influenced by AAV transgene. AV5LacZ (4 Â 10 9 vg kg À1 ) was, therefore, injected into the tail vein of B6.CB17-Prkdc-SzJ mice at 15 weeks following portal vein administration of 4 Â 10 12 vg kg
of rAAV-2 CAGG-tsFlk, a vector in which the hFIX cDNA has been replaced with the truncated soluble vascular endothelial growth factor receptor (tsFlk-1) cDNA. 24 Delayed administration of AV5LacZ resulted in an increase in tsFlk-1 plasma levels from 24 ± 2 to 50 ± 3 mg ml
, a result that is highly significant (Po0.0001 by Student's t-test). These studies in immunodeficient mice suggest that augmentation of AAV transgene expression observed following late administration of adenovirus is likely to be mediated by specific proteins transiently expressed by the adenoviral vector as opposed to a nonspecific consequence of inflammation that often follows the systemic administration of this virus in immunocompetent animals. Next, the influence of AAV promoter was assessed using AV5GFP, which is identical to AV5LacZ except that the b-galactosidase gene has been replaced with the green fluorescent protein cDNA.
25 AV5GFP (4 Â 10 9 vg kg À1 ) was administered into the tail vein of mice at 20 weeks after gene transfer with rAAV2-LPS-FIX, a vector in which the CAGG proviral promoter has been replaced with the a1-microglobulin/bikunin enhancer and thyroid hormonebinding globulin promoter (also referred to as liver-specific promoter). 24, 26 A threefold increase in steady-state hFIX from 0.02±0.007 to 0.07±0.006 mg ml À1 (P ¼ 0.005 by Student's t-test) was observed following delayed administration of recombinant adenovirus. These results indicate that the enhancement in rAAV transgene expression observed after late administration of adenovirus is not influenced by the vector transgene, proviral promoter, mouse strain, timing of adenovirus administration or the adenoviral vector cDNA.
To determine if late administration of adenovirus enhanced scAAV-mediated transgene expression, 4 Â 10 8 vg kg À1 of scAAV2/8-LP1-hFIXco was injected into the tail vein of two groups of 6-to 8-week-old C57Bl/6 male mice (N ¼ 3 per group). Eight weeks after scAAV transduction, one group received 4 Â 10 9 vg kg À1 of AV5GFP through the tail vein, while the other received excipient. Administration of AV5GFP increased the plasma hFIX levels by almost fourfold from 0.05±0.01 to 0.19 ± 0.02 mg ml
( Figure 5e ). This difference in expression is highly significant (P ¼ 0.02, by Student's t-test). Augmentation of scAAV-mediated transgene expression (hFIX) was also observed in animals transduced with a higher dose of scAAV (8 Â 10 10 vg kg
) following late administration of adenovirus. However, the difference between the adenovirus (7.38 ± 0.4 mg ml
) and the control (6.41 ± 0.3 mg ml À1 ) group was not statistically significant (P ¼ 0.07, by Student's t-test).
Discussion
Several distinct factors that influence AAV-mediated gene transfer of the murine liver were identified in this study including AAV capsid protein, gender, proteasome inhibition and late infection with adenoviral vectors. Comparison of the liver transduction efficiency of scAAV pseudotyped with capsids from four recently isolated non-human primate serotypes showed an almost linear relationship between vector dose and transgene expression. Expression of hFIX at therapeutic levels was documented with scAAV vector doses as low as 1 Â 10 7 vg per mouse (4 Â 10 8 vg kg À1 ). Irrespective of vector dose, scAAV vectors pseudotyped with serotype 8 or rh.10 capsid were more efficient at transducing the liver than scAAV2/7. Capsid proteins appeared to influence the efficiency with which the transgene was expressed, with scAAV2/9 vectors mediating at least twofold higher plasma levels of hFIX per copy of the transgene in hepatocytes when compared with the other serotypes evaluated. Gender had a significant impact on scAAV-mediated transgene expression from the liver, with twofold higher levels observed in male compared with female mice. Pretreatment of mice with bortezomib, a proteasome inhibitor that is in clinical use, increased scAAV-mediated transgene expression by at least 50%, with its effect more marked in female than in male mice. Unexpectedly, the administration of an early-generation recombinant adenoviral vector at 10-20 weeks after AAV gene transfer resulted in a two-to threefold increase in steady-state AAV transgene expression through a mechanism that augmented AAV proviral transcription or mRNA stability. Hence, multiple steps of the AAV gene transfer pathway, ranging from binding to the target cells, endosomal escape and molecular processing of the proviral DNA can be further optimized to enhance the potency of AAV.
The ability to pseudotype the AAV2 proviral genome with naturally occurring or synthetic capsid has generated a large series of new chimeric rAAV vectors with distinct biological properties. 10, 11, 22, [27] [28] [29] Among these, AAV2/8 vectors have received increased attention with numerous studies demonstrating highly efficient transduction of the murine liver with vectors based on this serotype when compared with rAAV2. This stems, at least in part, from the ability of rAAV2/8 to uncoat more rapidly resulting in a distinct profile of transgene expression with earlier establishment of steady-state levels (within 1 week) when compared with AAV2, where expression peaks at 4-6 weeks in mice. 7, 17 Identical transgene expression kinetics were observed with vectors pseudotyped with capsid from serotypes 7, 9 and rh.10, suggesting that these non-human primate isolates may also have similar uncoating properties. The differences in transgene expression between the various pseudotyped scAAV vectors and their biodistribution profile suggest that other factors such as viral binding and uptake by target cells are also important. Cellular binding of AAV-8 and AAV-9 appears to be mediated by the 37/67-kDa laminin receptor (LamR), but the receptors for serotypes 7 and rh.10 remain undefined. 30 Capsid proteins may also influence the efficiency of transgene expression, as noted in the cohort transduced with scAAV2/9. Consistent with the earlier reports, the mean plasma hFIX levels in the scAAV-2/8 and -2/9 groups of Liver transduction with adeno-associated viral vectors AC Nathwani et al mice were not significantly different because of the twofold higher level of transgenic protein per hepatocyte proviral copy in the mice transduced with scAAV2/9.
10,31
The mechanism by which serotype 9 capsid mediates higher expression per proviral copy needs to be defined. An important observation of our study is the similar high transduction efficiency observed with scAAV vectors pseudotyped with either serotype 8 or rh.10 capsid in mice. In addition, despite over 90% of aminoacid sequence homology between the capsid proteins, there appeared to be little humoral immune crossreactivity between these two AAV serotypes in mice, indicating that the neutralizing antibodies were directed against specific epitopes that are not common to the two serotypes. This encourages us to believe that patients who have been sensitized to serotype 8 vectors as a result of exposure to wt virus or recombinant vector can be effectively treated at a later time point with similar doses of vector pseudotyped with AAV-rh. 10 .
We have earlier demonstrated a 10-fold higher transduction of the liver in male mice compared with female mice when using single-stranded AAV vectors. 15 This gender effect appeared to be mediated by an interaction between the rep-binding site (RBS) within the AAV ITRs and a distinct androgen-dependent hepatocellular nuclear protein, which increased the hepatocyte transgene copy number and expression of the transgenic protein in males. We hypothesized that this gender difference, which has also been reported in dogs, was a result of enhanced AAV second-strand synthesis that was catalyzed by the interaction between the AAV ITR and the androgen-dependent RBS-binding nuclear protein. 15, 22, [32] [33] [34] The fact that we and others have observed a similar gender influence with scAAVmediated transgene expression, though to a lesser extent than single-stranded AAV vectors, suggests that the gender difference is because of a more complex mechanism that likely involves multiple pathways. 35 Interestingly, pretreatment of mice with bortezomib diminished the gender difference following scAAVmediated gene transfer. This to our knowledge is the first report of the gender-specific effects of bortezomib on scAAV-mediated gene transfer to the liver. Previously, peptide aldehyde inhibitors of the proteasome pathway have been shown to augment AAV-mediated transduction of fibroblasts, endothelial and pulmonary epithelial cells by preventing ubiquitination of viral particles. 16, 36 We speculate that in addition to reducing proteasomal degradation of scAAV2/8 vector particles, bortezomib may reduce ubiquitination of the RBS-binding nuclear protein, thus facilitating stable retention of the AAV genome in the target cells. Further studies are necessary to explore this and other possibilities as the gender difference in AAV-mediated transduction of the liver has significant implications for gene therapy of autosomal and acquired disorders affecting the liver.
An unexpected finding was the enhancement of AAV transgene expression following administration of adenovirus at 10-20 weeks after AAV gene transfer in immunodeficient and immunocompetent mice. We observed a similar effect with low doses of scAAV vectors pseudotyped with serotype 8 capsid, suggesting that this late effect of adenovirus is not influenced by capsid protein, genome configuration, mouse strain, AAV transgene and proviral promoter. Furthermore, adenovirus appears to have disparate effects on the AAV gene transfer pathway depending on the stage at which it is administered. Simultaneous infection with rAAV and adenoviral vectors results in an increase in rAAV transgene copy number through efficient conversion of the single-stranded genome to a stable transcriptionally active double-stranded form.
14 In contrast, late administration of adenovirus into a host previously transduced with rAAV results in an increase in transgene expression through a 10-fold increase in proviral transcription or mRNA stability without any significant change in the rAAV transgene copy number. Importantly, increase in rAAV mRNA level and transgene expression is maintained for at least 14 weeks in immunocompetent mice (Figure 5a ) despite the continuous immune-based elimination of the adenovirus-transduced cells during this period. Previous studies have shown that adenovirus influences the nuclear location of the AAV genome. 37 We, therefore, hypothesize that the expression of adenoviral proteins 10-20 weeks after AAV-mediated gene transfer changes the nuclear location of the AAV genome to a location that is more conducive to transgene expression.
Irrespective of the mechanism, these observations may have significant implications for the use of AAV vectors in the clinic. For disorders such as diabetes, where the therapeutic window is narrow, adenoviral infection may tip therapeutic AAV-mediated transgene expression into the toxic range. Alternatively, adenoviral infection may help to restore flagging AAV expression into the therapeutic range. This may be important for chronic disorders such for hemophilia, where natural turnover of hepatocytes over time may lead to a decline in transgene expression.
In summary, we have identified several different factors that augment hepatocyte gene transfer in mice. These results have significant implications for the translation of gene therapy to the clinic and merit further investigation in a context relevant to humans.
Materials and methods
AAV and adenoviral vector production and purification
The CAGG-FIX, CAGG-tsFlk and LPS-FIX plasmids have been described before. 15 rAAV-hFVII consists of the fulllength 2.4 kb human FVII cDNA under the control of the LP1 promoter and is flanked by AAV2 ITRs. The production of rAAV and scAAV vectors pseudotyped with capsid from alternative serotypes has been previously described. 7, 8 In brief, an adenoviral helper plasmid and chimeric AAV2 Rep-7Cap, -8Cap, -9Cap or rh.10Cap packaging plasmids were used to generate AAV-7, -8, -9 and -rh.10 pseudotyped vector particles. 10, 11, 22 The vector stocks were purified using iodixanol gradient and the vg titers were determined by our qPCR method using linear plasmid DNA as standards. The purified vector stocks were consistently free of contamination with wt AAV and cellular and adenoviral proteins as judged by our previously described methods. 23, 38 Adenoviral vector (AV5LacZ and AV) stocks were prepared as described previously. 25 
Animal studies and bioassays
All procedures were performed in accordance with institutional guidelines under protocols approved by the Institutional Biosafety Committee and the Institutional UK) and The Jackson Laboratory (Maine, USA), respectively. Tail vein administration of AAV and adenoviral vector particles was performed as described before. 7, 8 Blood samples were collected at regular intervals and assayed for the appropriate transgene (hFIX hFVII or ts-Flk-1) by the enzyme-linked immunosorbent assay. Methods for detection of hFIX and ts-Flk-1 have been described before. 23, 24 Human FVII levels in mouse plasma were assessed using the Asserachrom human FVII enzyme-linked immunosorbent assay kit (Axis-shield, Cambridgeshire, UK). The probability of statistical differences between experimental groups was determined by one-way analysis of variance and paired Student's t-test using GraphPad Prizm version 4.0 software (GraphPad, San Diego, CA, USA).
Molecular studies
To determine AAV transgene copy number, high molecular weight genomic DNA (10 mg) extracted from murine tissue samples, using our previously described method, 23, 39 was digested with BsrDI (for scAAV-LP1-hFIXco) or NheI (for CAGG-hFIX), electrophoresed through a 0.8% agarose gel, transferred to a nylon membrane (Hybond-N+; Amersham Biosciences, Amersham, UK) and then hybridized with an a 32 Plabeled 400 bp hFIX fragment at 42 1C. The intensity of the hybridization was determined using the STORM phosphorimager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). A qPCR assay, based on 2 Â IQ Supermix (Bio-Rad, Hercules, CA, USA) SYBR Green detection, was used to evaluate the biodistribution of scAAV-FIX vectors in genomic DNA extracted from various murine tissues using the following primers: forward primer, 5 0 -GGGCAAGTATGGCATCTACA-3 0 and reverse primer, 5 0 -AAAGCATCGAGTCAGGTCAG-3 0 . Integrity of the murine DNA was assessed using the following GAPDH primers: forward, 5 0 -GGAGTCCACT GGCGTCTTCAC-3 0 and reverse: 5 0 -GAGGCATTGCTGA TGATCTTGAGG-3 0 . The lower limit of sensitivity for this assay was determined to be 10 viral copies per mg genomic DNA. Total cellular RNA was isolated from 20 to 30 mg of liver tissue derived from cohorts transduced with AAV followed by late exposure to adenoviral vector using RNA STAT-60 (TEL TEST Inc., Friendswood, TX, USA). Approximately 10 mg of total RNA from each sample was subjected to denaturing agarose electrophoresis, transferred to nylon membrane (Hybond-N+; Amersham Biosciences, Arlington Heights, IL, USA) by northern blotting procedure. The blots were hybridized with an a 32 P-labeled FIX probe and the intensity of hybridization was determined as described above.
Detection of anti-AAV antibodies
An immunocapture assay was used to detect anti-AAV-specific antibodies in murine plasma as described before. 23 Results were expressed as the end point titer, defined as the reciprocal of the interpolated dilution with an absorbance value equal to five times the mean absorbance background value. Neutralizing antibody titers were assessed by determining the ability of murine serum to inhibit transduction of 293T cells by pseudotyped scAAV vector containing the enhanced green fluorescent protein cDNA under the control of the CMV promoter (scAAV CMV-GFP) as previously described. 39, 40 The neutralizing antibody titer is expressed as the dilution that inhibited the transduction of 293T cells by 50%.
